Globus Medical (GMED) CG 2025 Musculoskeletal Conference summary

Strategic overview and integration progress

• Completed merger with NuVasive in September 2023, combining innovative technologies and expanding reach to more surgeons domestically and internationally.

• Achieved $94 million in synergies in the first year post-merger, with a three-year target of $170 million.

• Focused on insourcing manufacturing and international integration in year two, expecting further efficiency gains and synergy realization into 2026.

• High sales force retention and increased interest from experienced reps, attributed to competitive commission rates and strong technology platform.

• Capital allocation priorities include paying down NuVasive debt, investing in product development, inventory, and strategic M&A.

Financial performance and guidance

• 2024 marked by 5% pro forma growth despite sales headwinds from integration.

• 2025 standalone guidance: $2.66–$2.69 billion revenue, $3.40–$3.50 non-GAAP EPS; with Nevro acquisition, $2.8–$2.9 billion revenue, $3.10–$3.40 non-GAAP EPS.

• Gross profit expected at 67.5%–68.5%, R&D investment at 6%–7%, CapEx at 5%–6% of sales.

• Seasonality: Q4 is peak, Q1 dips, Q2 and Q3 stable with Q2 slightly higher due to capital sales.

• Focus on returning to mid-30s adjusted EBITDA margins, with gross profit improvements expected sooner due to insourcing and Nevro integration.

Product innovation and pipeline

• Launched 18 new products in 2024, including DuraPro oscillating drill for soft tissue protection and EFlex knee robotic system.

• Reline pedicle screw system now FDA-cleared for navigation and integration with Excelsius robotic system.

• Precice limb lengthening nail highlighted as a key trauma technology.

• Continued focus on expanding hip and knee replacement technologies, aiming for a more competitive product bag by late 2024.